Clinical trials: Pulmonary Hypertension Chronic Thromboembolic
Pulmonary Hypertension
BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension
Patients who have completed the 16 weeks treatment of the CHEST-1 trial (study number 11348) will be asked to participate in this long term extension study with BAY63-2521.
- Trial name
- CHEST-2 (NCT00910429)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 73 sites in United States, Argentina and 24 more
- Volunteers
- 237 people
- Sponsor
- Bayer
Chronic Thromboembolic Pulmonary Hypertension
A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
The purpose of the study is to evaluate the effect of macitentan 75 mg versus placebo on exercise capacity at Week 28 in participants with chronic thromboembolic pulmonary hypertension (CTEPH).
- Trial name
- MACiTEPH (NCT04271475)
- Testing
- Macitentan
- Where
- 168 sites in United States, Argentina and 31 more
- Volunteers
- 127 people
- Sponsor
- Actelion
Hypertension, Pulmonary
A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice
The aim of this study is to understand the treatment patterns in patients with Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH) during a switch of treatment to Adempas in real-life…
- Trial name
- CAPTURE (NCT02545465)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 7 sites in Belgium, Canada and 5 more
- Volunteers
- 125 people
- Sponsor
- Bayer
Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension
Effect of Long-term Oxygen Therapy on Exercise Capacity and Quality of Life in Patients With Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension
In this randomized-controlled, cross-over trial the investigators test the effect of long-term oxygen therapy (> 16h/day) given for 5 weeks with a wash-out period between phases of 2 weeks on exercise performance and quality of…
- Trial name
- NCT01884012
- Testing
- long term oxygen therapy
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- University of Zurich
Venous Thromboembolism (VTE), Chronic Thromboembolic Pulmonary Hypertension
Pulmonary Embolism Registry From Short-Term Emergency to Long-Term Follow-Up and Surveillance
PERSEUS is an academic, investigator-initiated, multicenter observational registry of adults with acute pulmonary embolism (PE), promoted by Azienda Ospedaliero-Universitaria Careggi (Florence, Italy).
- Conditions
- Venous Thromboembolism (VTE), Chronic Thromboembolic Pulmonary Hypertension, Right Ventricular Dysfunction, Pulmonary Embolism (PE)
- Trial name
- PERSEUS (NCT07855679)
- Testing
- Routine clinical care (no study intervention)
- Where
- 16 sites in Italy, Poland and 1 more
- Volunteers
- 5,000 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Hypertension, Pulmonary, Pulmonary Thromboembolisms
Functional Pulmonary Capillary Surface Area in BPA for CTEPH
Chronic thromboembolic pulmonary hypertension [CTEPH] is caused by pulmonary emboli that have enlarged in pulmonary arteries and have become organized into the vessel wall.
- Trial name
- NCT05719415
- Testing
- Measurement of pulmonary functional capillary surface area
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Jewish General Hospital
Chronic Thromboembolic Pulmonary Hypertension
The Role of Matrix Metalloproteinase 2 and 9 Enzymes in Developing Chronic Thromboembolic Pulmonary Hypertension
Chronic thromboembolic pulmonary hypertension is an occlusive disease in pulmonary artery.Matrix metalloproteinase enzymes play a substantial role of extracellular matrix remodeling.
- Trial name
- NCT04773028
- Testing
- matrix metalloproteinase enzymes 2 and 9
- Where
- Turkey (Türkiye)
- Volunteers
- 48 people
- Sponsor
- AHMET ZENGIN
Pulmonary Vascular Disorder, Chronic Thromboembolic Pulmonary Hypertension
Exercise Performance on Ambient Air vs. Low-Flow Oxygen Therapy in Pulmonary Vascular Disease (PVD)
The investigators aim to study the effect of SOT in Swiss residents with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH).
- Conditions
- Pulmonary Vascular Disorder, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Arterial Hypertension
- Trial name
- NCT06384534
- Testing
- 6-minute walk distance (6MWD) test on ambient air, 6-minute walk distance test with supplemental oxygen
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- University of Zurich
Pulmonary Hypertension, Chronic Thromboembolic Pulmonary Hypertension
the Application of Cardiopulmonary Exercise Testing in Assessment Outcome of Patients With Pulmonary Hypertension
cardiopulmonary exercise test evaluate patients with pulmonary hypertension before and after medical or balloon pulmonary angioplasty treatment
- Conditions
- Pulmonary Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder)
- Trial name
- CPETPH (NCT02061787)
- Testing
- balloon pulmonary angioplasty
- Where
- China
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Chinese Pulmonary Vascular Disease Research Group
Hypertension, Pulmonary
A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option
The purpose of the study is to enable participants with pulmonary hypertension (PH) currently treated with study intervention(s) in a clinical study (parent studies [NCT03422328, NCT03904693,NCT04565990, NCT02932410, NCT03492177…
- Trial name
- PLATYPUS (NCT05179876)
- Testing
- Macitentan, Selexipag, Macitentan/Tadalafil FDC
- Where
- 45 sites in Belarus, Belgium and 11 more
- Volunteers
- 280 people
- Sponsor
- Actelion